1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 23, 33, 4, 118, 48 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 54 and 13 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionObesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Obesity, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Obesity - Pipeline by Aardvark Therapeutics Inc, H2 2020
- Obesity - Pipeline by Adare Pharma Solutions, H2 2020
- Obesity - Pipeline by Adipo Therapeutics LLC, H2 2020
- Obesity - Pipeline by Adocia SAS, H2 2020
- Obesity - Pipeline by AgeX Therapeutics Inc, H2 2020
- Obesity - Pipeline by Alla Chem LLC, H2 2020
- Obesity - Pipeline by Altimmune Inc, H2 2020
- Obesity - Pipeline by Amgen Inc, H2 2020
- Obesity - Pipeline by Anagenesis Biotechnologies SAS, H2 2020
- Obesity - Pipeline by Antag Therapeutics ApS, H2 2020
- Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2020
- Obesity - Pipeline by Applied Molecular Transport Inc, H2 2020
- Obesity - Pipeline by AptamiR Therapeutics Inc, H2 2020
- Obesity - Pipeline by Aptorum Group Ltd, H2 2020
- Obesity - Pipeline by Armata Pharmaceuticals, H2 2020
- Obesity - Pipeline by AstraZeneca Plc, H2 2020
- Obesity - Pipeline by Athersys Inc, H2 2020
- Obesity - Pipeline by Auris Medical Holding Ltd, H2 2020
- Obesity - Pipeline by Betagenon AB, H2 2020
- Obesity - Pipeline by BioRestorative Therapies Inc, H2 2020
- Obesity - Pipeline by Biozeus Pharmaceutical SA, H2 2020
- Obesity - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Obesity - Pipeline by Braasch Biotech LLC, H2 2020
- Obesity - Pipeline by Bukwang Pharmaceutical Co Ltd, H2 2020
- Obesity - Pipeline by Caliway Biopharmaceutics Co Ltd, H2 2020
- Obesity - Pipeline by Callitas Therapeutics Inc, H2 2020
- Obesity - Pipeline by Can-Fite BioPharma Ltd, H2 2020
- Obesity - Pipeline by Carmot Therapeutics Inc, H2 2020
- Obesity - Pipeline by Cellivery Therapeutics Inc, H2 2020
- Obesity - Pipeline by Celon Pharma SA, H2 2020
- Obesity - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2020
- Obesity - Dormant Projects, H2 2020
- Obesity - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Obesity, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aardvark Therapeutics Inc
- Adare Pharma Solutions
- Adipo Therapeutics LLC
- Adocia SAS
- AgeX Therapeutics Inc
- Alla Chem LLC
- Altimmune Inc
- Amgen Inc
- Anagenesis Biotechnologies SAS
- Antag Therapeutics ApS
- Aoxing Pharmaceutical Company Inc
- Applied Molecular Transport Inc
- AptamiR Therapeutics Inc
- Aptorum Group Ltd
- Armata Pharmaceuticals
- AstraZeneca Plc
- Athersys Inc
- Auris Medical Holding Ltd
- Betagenon AB
- BioRestorative Therapies Inc
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Braasch Biotech LLC
- Bukwang Pharmaceutical Co Ltd
- Caliway Biopharmaceutics Co Ltd
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Carmot Therapeutics Inc
- Cellivery Therapeutics Inc
- Celon Pharma SA
- Centeer BioTherapeutics Ltd Co
- Chong Kun Dang Pharmaceutical Corp
- Clayton Biotechnologies Inc
- CohBar Inc
- Corbus Pharmaceuticals Inc
- Corcept Therapeutics Inc
- Cyrus Therapeutics
- D&D Pharmatech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- DD Therapeutics LLC
- Diasome Pharmaceuticals Inc
- DiscoveryBiomed Inc
- Eli Lilly and Co
- Empros Pharma AB
- EncuraGen Inc
- Eolo Pharma
- EraCal Therapeutics AG
- Eternygen GmbH
- Evecxia Inc
- FGH BioTech Inc
- Fzata Inc
- Gila Therapeutics Inc
- Glaceum Inc
- Glucox Biotech AB
- Gmax Biopharm Ltd
- GPER G-1 Development Group LLC
- Gubra ApS
- HanAll Biopharma Co Ltd
- Hangzhou Adamerck Pharmlabs Inc
- Hangzhou Jiuyuan Gene Engineering Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Helsinn Group
- Ildong Pharmaceutical Co Ltd
- Immune Biosolutions Inc
- Immungenetics AG
- ImmunoBiome Inc
- Infusion Biosciences
- Innovimmune Biotherapeutics Inc
- Intarcia Therapeutics Inc
- Japan Tobacco Inc
- Jenrin Discovery Inc
- Johnson & Johnson
- Juno Therapeutics Inc
- Kallyope Inc
- KinDex Pharmaceuticals Inc
- Kintai Therapeutics Inc
- Kissei Pharmaceutical Co Ltd
- KoBioLabs Inc
- Kriya Therapeutics Inc
- Kwang Dong Pharmaceutical Co Ltd
- Lead Discovery Center GmbH
- LG Chem Ltd
- Lipidio Pharmaceuticals Inc
- Living Cell Technologies Ltd
- Lixte Biotechnology Holdings Inc
- LNC Therapeutics SA
- Lobesity LLC
- Lynkogen Inc
- MAKScientific LLC
- MD Healthcare Inc
- MeiraGTx Holdings Plc
- Merck & Co Inc
- Mirabilis Therapeutics BV
- Nano Intelligent Biomedical Engineering Corp
- NeuroNano Pharma Inc
- NGM Biopharmaceuticals Inc
- Nordic Bioscience AS
- Novartis AG
- NovMetaPharma Co Ltd
- Novo Nordisk AS
- Nubiyota LLC
- NuSirt Biopharma Inc
- ObeTherapy Biotechnology
- Omeros Corp
- Onegene Biotechnology Inc
- OPKO Health Inc
- Oramed Pharmaceuticals Inc
- Orbit Discovery Ltd
- Oxt Therapeutics Inc
- Palatin Technologies Inc
- PegBio Co Ltd
- Pfizer Inc
- Preveceutical Medical Inc
- Pylum Biosciences Inc
- Raziel Therapeutics
- Regeneron Pharmaceuticals Inc
- Renova Therapeutics Inc
- Repurpose.AI Inc
- Reviva Pharmaceuticals Inc
- Rhamnopharma Inc
- Rhythm Pharmaceuticals Inc
- Saniona AB
- Sanofi
- Scioto Biosciences Inc
- Scohia Pharma Inc
- Senda Biosciences Inc
- Seres Therapeutics Inc
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shionogi & Co Ltd
- Sigrid Therapeutics AB
- Siragen Pharmaceuticals Inc
- SJT Molecular Research SL
- Soleno Therapeutics Inc
- Sun Pharmaceutical Industries Ltd
- Symmetry Therapeutics Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Co Ltd
- Talapo Therapeutics Inc
- Techfields Pharma Co Ltd
- UGISense AG
- Uni-Bio Science Group Ltd
- Velabs Therapeutics GmbH
- Virtici LLC
- Vivus Inc
- XL-protein GmbH
- Yuhan Corp
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
- Zihipp Ltd
